ASLAN Reports First Patient Enrollment in P-IIb (TREK-AD) Study of ASLAN004 (eblasakimab) for the Treatment of Atopic Dermatitis
Shots:
- The 1st patient has been enrolled in P-IIb (TREK-AD) dose-ranging clinical study to evaluate efficacy & safety of eblasakimab (300/400mg, q2w, 400/600mg, q4w) in 300 patients with AD across 100 sites in North America, EU & Asia Pacific. The results from the 16wk. treatment period is expected in H1’23
- The primary efficacy EPs is the percentage change in EASI score from baseline to 16wk. The 2EPs include the proportion of patients who achieve an IGA score of 0 (clear) or 1 (almost clear), ≥75% reduction in EASI-75 & achieve EASI-50 & 90 & changes in peak pruritus
- Eblasakimab is a mAb targeting IL-13 receptor & has the potential to provide a differentiated treatment option for patients
Ref: Globe Newswire | Image: Stock Light
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com